Jose Rivera Biography and Net Worth

Jose E. Rivera J.D. serves as Executive Vice President, General Counsel of the Company. Previously served as our chief operating officer and chief legal officer from April 2015 to January 2017. He joined Intellia in July 2014 as our general counsel and chief talent officer. Prior to joining Intellia, Mr. Rivera was the vice president, chief ethics and compliance officer at AbbVie from its spin-out from Abbott in January 2013 until September 2013. From 1996 to 2012, Mr. Rivera was a member of Abbott’s legal division serving in a number of positions of increasing responsibilities, including leading various legal groups as division vice president and associate general counsel, such as Abbott’s global intellectual property group, intellectual property litigation department, legal regulatory department and litigation department. Mr. Rivera is a member of the board of directors of the North Suburban Legal Aid Clinic (Illinois). Mr. Rivera received his B.A. in economics from Boston College and his J.D. from Harvard Law School.

What is Jose E. Rivera's net worth?: The estimated net worth of Jose E. Rivera is at least $2.34 million as of April 1st, 2021. Mr. Rivera owns 148,842 shares of Intellia Therapeutics stock worth more than $2,338,308 as of November 14th. This net worth approximation does not reflect any other assets that Mr. Rivera may own. Learn More about Jose E. Rivera's net worth.
How do I contact Jose E. Rivera?: The corporate mailing address for Mr. Rivera and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on Jose E. Rivera's contact information.
Has Jose E. Rivera been buying or selling shares of Intellia Therapeutics?: Jose E. Rivera has not been actively trading shares of Intellia Therapeutics during the last ninety days. Most recently, Jose E. Rivera sold 50,455 shares of the business's stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $82.46, for a transaction totalling $4,160,519.30. Following the completion of the sale, the executive vice president now directly owns 148,842 shares of the company's stock, valued at $12,273,511.32. Learn More on Jose E. Rivera's trading history.
Who are Intellia Therapeutics' active insiders?: Intellia Therapeutics' insider roster includes Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.
Are insiders buying or selling shares of Intellia Therapeutics?: In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company. Learn More about insider trades at Intellia Therapeutics.
Information on this page was last updated on 10/2/2024.

Jose E. Rivera Insider Trading History at Intellia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2021	Sell	50,455	$82.46	$4,160,519.30	148,842
2/9/2021	Sell	11,489	$75.00	$861,675.00	129,409
2/1/2021	Sell	54,659	$63.99	$3,497,629.41	120,068
1/5/2021	Sell	2,078	$55.86	$116,077.08
12/1/2020	Sell	3,364	$38.21	$128,538.44	52,072
11/18/2020	Sell	624	$35.00	$21,840.00	52,315
11/16/2020	Sell	6,029	$34.29	$206,734.41	52,315
11/4/2020	Sell	3,364	$28.00	$94,192.00	45,679
10/15/2020	Sell	5,615	$24.20	$135,883.00	46,294
9/15/2020	Sell	5,615	$21.04	$118,139.60	41,909
8/18/2020	Sell	5,615	$21.00	$117,915.00	37,524
7/15/2020	Sell	5,615	$22.70	$127,460.50
6/16/2020	Sell	5,615	$21.00	$117,915.00	27,897
5/26/2020	Sell	5,615	$21.21	$119,094.15

Jose E. Rivera Buying and Selling Activity at Intellia Therapeutics

Intellia Therapeutics Company Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $15.71

$15.60

$16.28

50 Day Range

MA: $18.87

$14.22

$22.93

2 Week Range

Now: $15.71

$13.95

$34.87

Volume

705,634 shs

Average Volume

1,666,531 shs

Market Capitalization

$1.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.